Extended Data Fig. 7: LND-CDN treatment of STING-/- mice and CDN response of MC38 cells in vitro. | Nature Materials

Extended Data Fig. 7: LND-CDN treatment of STING-/- mice and CDN response of MC38 cells in vitro.

From: STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity

Extended Data Fig. 7

a,b, Groups of STING-/- mice on the C57Bl/6 background (n = 6 (PBS) or 5 (LND-CDN) animals/group) were inoculated with 5 × 105 MC38 tumour cells in the flank. Seven days later, animals were treated once by i.v. injection with 5 nmol LND-CDN or saline control. Shown are tumour growth (mean ± s.e.m.) (a) and overall survival (b). Statistical comparisons between tumour growth curves were made by an unpaired, two-tailed Student’s t-test; survival curves were statistically compared using a log-rank (Mantel–Cox) test. (c) MC38 tumour cells were incubated with a range of parent CDN concentrations in complete media for 24 hours and, subsequently, cell viability was assessed using a resazurin-based in vitro toxicology assay kit (Millipore Sigma) as per the manufacturer’s instructions. Each point represents the mean of four replicates (±s.e.m.). d, The number of live tumour endothelial cells per milligram of tumour (mean ± s.e.m.) was quantified by flow cytometry 24 h after treatment of MC38 tumours with LND-CDN or liposome-CDN, compared to untreated tumours (n = 5 mice per group). Statistical comparisons were made with a one-way ANOVA with Tukey’s multiple comparisons test.

Back to article page